Literature DB >> 9299549

Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2.

J Lövgren1, K Rajakoski, M Karp, H Lilja.   

Abstract

Prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) are glandular kallikreins secreted by the prostate gland. Both enzymes are synthesized with a propeptide that is supposedly cleaved off in the prostate to yield the mature forms found in semen. We have purified and characterised recombinant PSA and hK2 produced in eucaryotic cells. Recombinant PSA was recovered as a zymogen and recombinant hK2 was recovered in mature form. The zymogen form of PSA had no or very low enzymatic activity. After incubation with hK2, proPSA was activated, as shown by the cleavage of the seminal gel proteins and a peptide substrate; the hK2-proPSA ratio used was similar to the enzyme-substrate ratio that prevails under phyciological conditions. Our results indicate that hK2 is responsible for the activation of proPSA, a finding that may be very important for understanding of the role of these two kallikreins in the reproductive system and in prostate cancer biology. Copyright 1997 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9299549     DOI: 10.1006/bbrc.1997.7333

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  33 in total

1.  Expression and characterization of trypsinogen produced in the human male genital tract.

Authors:  A Paju; A Bjartell; W M Zhang; S Nordling; A Borgström; J Hansson; U H Stenman
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

2.  Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.

Authors:  Yue Cao; Ake Lundwall; Virgil Gadaleanu; Hans Lilja; Anders Bjartell
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

3.  PSA regulates androgen receptor expression in prostate cancer cells.

Authors:  Parmita Saxena; Marco Trerotola; Tao Wang; Jing Li; Aejaz Sayeed; Jennifer Vanoudenhove; Dave S Adams; Thomas J Fitzgerald; Dario C Altieri; Lucia R Languino
Journal:  Prostate       Date:  2011-09-28       Impact factor: 4.104

4.  Twenty Years of PSA: From Prostate Antigen to Tumor Marker.

Authors:  Gabriela De Angelis; Harry G Rittenhouse; Stephen D Mikolajczyk; L Blair Shamel; Axel Semjonow
Journal:  Rev Urol       Date:  2007

Review 5.  New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family.

Authors:  Nashmil Emami; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2007-09-15       Impact factor: 6.603

6.  Activation profiles of human kallikrein-related peptidases by matrix metalloproteinases.

Authors:  Hyesook Yoon; Sachiko I Blaber; Wu Li; Isobel A Scarisbrick; Michael Blaber
Journal:  Biol Chem       Date:  2013-01       Impact factor: 3.915

7.  Trypsin-like proteolytic contamination of commercially available psa purified from human seminal fluid.

Authors:  Michael L Manning; Maya Kostova; Simon A Williams; Samuel R Denmeade
Journal:  Prostate       Date:  2011-12-28       Impact factor: 4.104

8.  Prostate-specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate-targeted PSA/KLK2 double transgenic mice.

Authors:  Simon A Williams; Yi Xu; Angelo M De Marzo; John T Isaacs; Samuel R Denmeade
Journal:  Prostate       Date:  2010-05-15       Impact factor: 4.104

9.  Activation profiles of human kallikrein-related peptidases by proteases of the thrombostasis axis.

Authors:  Hyesook Yoon; Sachiko I Blaber; D Michael Evans; Julie Trim; Maria Aparecida Juliano; Isobel A Scarisbrick; Michael Blaber
Journal:  Protein Sci       Date:  2008-08-12       Impact factor: 6.725

Review 10.  [Serum markers for early detection and staging of prostate cancer. Status report on current and future markers].

Authors:  A Haese; M Graefen; J Palisaar; E Huland; H Huland
Journal:  Urologe A       Date:  2003-09       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.